Company Overview - Mingzhi Technology Co., Ltd. is a platform-based medical device company specializing in innovative visualization and minimally invasive medical devices, particularly in the disposable urological endoscope sector [3] - The company operates in Silicon Valley and China, focusing on the research and commercialization of disposable endoscope systems [3] - Mingzhi Technology is one of the few companies globally that has successfully achieved vertical integration of the disposable endoscope supply chain, covering everything from core optoelectronic components and precision parts to complete system assembly [3] Product Portfolio - The product portfolio includes two main categories: 1. Disposable endoscopes designed for specific clinical applications such as ureteroscopes, cystoscopes, and bronchoscopes, featuring patented micro-camera modules and industry-leading micro-joint technology [4] 2. Image processors compatible with capital equipment, utilizing advanced algorithms to ensure excellent image quality and seamless user experience [4] - As of the last practicable date, the company has eight approved product categories and five in-development product categories in major global markets, including the US, EU, and China [4] Financial Performance - For the fiscal years 2023, 2024, and the nine months ending September 30, 2025, the company reported revenues of approximately RMB 135.16 million, RMB 141.05 million, and RMB 117 million, respectively [10] - The net profit for the same periods was approximately RMB 49.99 million, RMB 66.67 million, and RMB 49.92 million [10] - The gross profit margins for 2023, 2024, and the nine months ending September 30, 2025, were 69.1%, 72.6%, and 73.7%, respectively [12] Industry Overview - The global endoscope market is projected to grow from USD 16 billion in 2020 to USD 36.5 billion by 2032, with a compound annual growth rate (CAGR) of 9.5% from 2020 to 2024 and an estimated 5.9% from 2024 to 2032 [13] - The disposable endoscope market is expected to expand from USD 700 million in 2020 to USD 9 billion by 2032, with a robust CAGR of 37.8% from 2020 to 2024, slowing to 17.2% from 2024 to 2032 [16] - The fastest-growing segments within the disposable endoscope market are urology and respiratory fields, both exceeding a 34-35% CAGR in the early stages [16][17]

Company Overview - Mingzhi Technology Co., Ltd. is a platform-based medical device company specializing in innovative visualization and minimally invasive medical devices, particularly in the disposable urological endoscope sector [3][4] - The company operates in Silicon Valley and China, focusing on the research and commercialization of disposable endoscope systems [3] - Mingzhi Technology is one of the few companies globally that has successfully achieved vertical integration of the disposable endoscope supply chain, covering everything from core optoelectronic components and precision parts to complete system assembly [3] Product Portfolio - The product portfolio includes two main categories: 1. Disposable endoscopes designed for specific clinical applications such as ureteroscopes, cystoscopes, and bronchoscopes, featuring patented micro-camera modules and industry-leading micro-joints with up to 275 degrees of bidirectional deflection [3] 2. Image processors compatible with capital equipment, utilizing advanced algorithms to ensure excellent image quality and seamless user experience [3] - As of the last practicable date, the company has eight approved product categories and five in-development product categories across major global markets, including the US, EU, and China [4] Financial Performance - For the fiscal years ending September 30, 2023, 2024, and 2025, the company reported revenues of approximately RMB 135.16 million, RMB 141.05 million, and RMB 117 million, respectively [7] - The net profit for the same periods was approximately RMB 49.99 million, RMB 66.67 million, and RMB 49.92 million [7] - The gross profit margins for the fiscal years 2023, 2024, and 2025 were 69.1%, 72.6%, and 73.7%, respectively [8] Industry Overview - The global endoscope market is expected to grow from USD 16 billion in 2020 to USD 36.5 billion by 2032, with a compound annual growth rate (CAGR) of 9.5% from 2020 to 2024 and an estimated 5.9% from 2024 to 2032 [9] - The disposable endoscope market is projected to expand from USD 700 million in 2020 to USD 9 billion by 2032, with a robust CAGR of 37.8% from 2020 to 2024, slowing to 17.2% from 2024 to 2032 [12][15] - The respiratory and urological fields are the largest and fastest-growing segments, with early-stage CAGRs exceeding 34-35% [12][13]

Core Viewpoint - The announcement highlights that Guangzhou Welly Medical Instrument Co., Ltd.'s subsidiary, Suzhou Medexin Medical Technology Co., Ltd., has received a Class II medical device registration certificate for its image processor, which is expected to enhance the company's market competitiveness in the medical device sector [1][3]. Group 1: Medical Device Registration Details - The registration certificate was issued by the Jiangsu Provincial Drug Administration with the registration number Su Xie Zhu Zheng 20252061723 [1]. - The product, an image processor, consists of a display screen, power adapter, image processing module (available in wired and wireless connections), and accessories including a display holder and hex screws [1][2]. - The approval date for the registration is September 2, 2025, and it is valid until September 1, 2030 [3]. Group 2: Impact on the Company - The image processor is designed to be used in conjunction with the company's visual products for effective display of the camera's observed field during diagnosis and surgery [2][3]. - The acquisition of the medical device registration certificate is anticipated to positively impact the company's operations and enhance the competitiveness of its visual products in the market [3].

Group 1 - The core point of the article is that Weili Medical (603309) announced that its subsidiary, Suzhou Medtronic Medical Technology Co., Ltd., has received a medical device registration certificate from the Jiangsu Provincial Drug Administration for its image processor product [1] Group 2 - The product name registered is "Image Processor" [1] - The announcement was made on the evening of September 4 [1] - The registration certificate is a significant regulatory milestone for the company [1]

Core Viewpoint - Weili Medical (603309.SH) announced that its subsidiary, Suzhou Medtronic Medical Technology Co., Ltd., has received a Class II medical device registration certificate for its image processor product, which enhances the competitiveness of the company's visual products in the market [1]. Group 1 - The product is designed for clinical use in displaying images of the observation field during diagnosis and treatment in human body cavities and surgeries [1]. - The registration certificate was issued by the Jiangsu Provincial Drug Administration, indicating regulatory approval for the product [1]. - The approval is expected to have a positive impact on the company's operations and market position [1].

Core Viewpoint - Weili Medical (603309.SH) announced that its subsidiary, Suzhou Medtronic Medical Technology Co., Ltd., has received the Medical Device Registration Certificate from the Jiangsu Provincial Drug Administration for its image processor product, which enhances the competitiveness of the company's visual products in the market [1] Group 1 - The product is designed for clinical use in conjunction with the company's visual products, effectively displaying images of the observed field during diagnosis and surgery [1] - The acquisition of the medical device registration certificate is expected to have a positive impact on the company's operations [1]

Core Viewpoint - The company, Weili Medical (603309.SH), has received a medical device registration certificate from the Jiangsu Provincial Drug Administration for its image processor product, which is designed for use in conjunction with the company's visual products during diagnostic and surgical procedures [1]. Group 1 - The product is intended to effectively display images of the observed field during diagnosis and treatment within the human body [1]. - The image processor will be utilized in clinical settings alongside the company's existing visual products [1]. - The approval from the regulatory authority enhances the company's product portfolio and potential market offerings in the medical device sector [1].

Group 1 - The company, Weili Medical (603309.SH), announced that its subsidiary, Suzhou Medtronic Medical Technology Co., Ltd. (referred to as "Suzhou Medtronic"), has recently received a Medical Device Registration Certificate from the Jiangsu Provincial Drug Administration [1] - The product named "Image Processor" is designed to be used in conjunction with the company's and its subsidiaries' visual products for effective display of the imaging area observed by the camera during diagnosis and treatment in human body cavities and surgeries [1]